Global Neurodegenerative Drugs Market To 2022: Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis and multiple sclerosis

Worldwide Market studies the current scenario as well as future market potential of "Global Neurodegenerative Drugs Market To 2022 - Growth Driven By An Aging Population, The Approval Of Novel Immunomodulators And Neuromodulators, And Strong Uptake Of Marketed Anti-Inflammatory Treatments"

Neurodegenerative disorders are a cluster of conditions that affect the central nervous system. They include both hereditary and sporadic conditions that are characterized by slow, irreversible, progressive dysfunction of the nervous system with the increasing degeneration of neurons, which causes symptoms such as motor impairment, memory loss and declining cognitive ability. Neurodegenerative disorders cannot currently be cured, and treatment is aimed at managing the disease indication in order to reduce the severity of symptoms and slow progression.

The report focuses on five key indications within neurodegenerative disorders: Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis and multiple sclerosis. With no curative therapies available, symptomatic medications prescribed off-label are an important part of the treatment paradigm, especially in amyotrophic lateral sclerosis and multiple sclerosis. This indicates the need for extensive R&D within this area.

Immunomodulators are the most effective and most common therapies used in neurodegenerative disorders. This class of compounds has been the most commercially successful in the past decade, particularly in the multiple sclerosis market, with many clinical trials underway for amyotrophic lateral sclerosis. The market for neurodegenerative disorders is largely accounted for by premium products, with generic products holding only a relatively small share. However, some generic products have been able to secure sizable market shares after the patent expiries of leading drugs. Glatopa (a generic version of Copaxone) recently entered the market and is expected to reach sales of $233m within the forecast period.

Get The Sample Copy Of This Report: http://www.marketresearchreports.biz/sample/sample/938605

Although there is a high degree of failure and uncertainty within the R&D of neurodegenerative disorder drugs, the number of drugs in the pipeline is very high, at 1,494. The majority of pipeline products are novel active pharmaceutical ingredients, with only a small proportion of products being either generics or repositioned from other indications. This shows progression in terms of the variety of molecules being developed as therapeutic agents within the neurodegenerative disorders pipeline. The market is expected to grow over the forecast period, which is attributed to the approval of new drugs, as well as the increasing aging population.

Scope

Global revenues for the neurodegenerative disorders market are forecast to grow at a compound annual growth rate of 7.42%, from $27.2 billion in 2015 to $45 billion in 2022. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
The neurodegenerative disorders pipeline is large and diverse, and contains 1,494 products. How does the composition of the pipeline compare with that of the existing market?
What mechanisms of action and molecule types are being trialed most commonly in pipeline products for the key indications?
Which products will contribute most significantly to market growth, and which will achieve blockbuster status?
Will the current market leaders retain their dominance over the forecast period, and how is their revenue share set to change?

Browse More Pharmaceutical Market Research Reports: http://www.marketresearchreports.biz/category/38

Reasons to buy

This report will allow you to -

Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis
Visualize the composition of the neurodegenerative disorders market across each indication, in terms of dominant molecule types and targets, and key commercial assets and players
Analyze the neurodegenerative disorders pipeline and stratify by stage of development, molecule type and molecular target, making use of a granular breakdown across key indications
Understand the growth in patient epidemiology and market revenues for the neurodegenerative disorders market, globally and across the key players and product types
Stratify the market in terms of the split between generic and premium products, and assess the role of these product types in the treatment of the various neurodegenerative disorders
Identify commercial opportunities in the neurodegenerative disorders deals landscape by analyzing trends in licensing and co-development deals

To View The Latest Industry Press Releases: http://www.marketresearchreports.biz/pressreleases

Contact us

90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E-Mail: sales@marketresearchreports.biz
Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports-biz
Thanks………..!!!!!!!!!!!

MarketResearchReports.biz supports your business intelligence needs with over 100,000 market research reports, company profiles, data books, and regional market data sheets in its repository. Our document database is updated by the hour, which means that you always have access to fresh data spanning over 300 industries and their sub-segments.

State Tower
90 State Street, Suite 700
Albany, NY 12207
United States

Toll Free: 866-997-4948
(USA-CANADA)

Tel: +1-518-621-2074
E: sales@marketresearchreports.biz

This release was published on openPR.